While beneficial, rapid weight reduction can lead to nutritional deficiencies in some patients
Meanwhile, Nestle, which owns Vital Proteins, launched a completely separate brand called Vital Pursuit targeting people already on GLP-1 medications
Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
ORM-6151 (BMS-986497) is currently being clinically evaluated in patients with AML and MDS, while the pre-clinical ORM-1153 may expand Orums presence into additional hematologic malignancies.
Results from Semaglutide weight loss treatments vary, but many patients notice significant changes within the first months
Key information to disclose includes: Medication name and dose "I take Wegovy (semaglutide) 2.4 mg once weekly by subcutaneous injection" Duration of treatment how long you have been taking Wegovy and whether you are still in the dose-escalation phase Current side effects any ongoing nausea, vomiting, diarrhoea, dizziness, or other symptoms Reason for prescription whether prescribed for obesity alone or with comorbidities such as type 2 diabetes, hypertension, or cardiovascular disease Overall health status current weight, blood pressure, and general wellbeing Donation staff will ask about your medical history and may need to consult with medical advisors regarding Wegovy